
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Virginia Carnahan, vice president of new product planning and strategy at Vertex Pharmaceuticals, reflects on the industry’s changing environment and how to adapt to remain competitive.






